In the general population, changes in mid-regional pro-atrial natriuretic peptide (MR-proANP) levels are commonly utilized to identify individuals at elevated risk for developing AF, cardioembolic stroke, and subsequent cardiovascular events following stroke [29,30]. The gene discussed is NR3C2; the disease is atrial fibrillation.